The European (bio) pharmaceutical industry emphasizes the importance of tailor-made therapy
In a press release, just before the start of the European Alliance for Personalized Medicine (EAPM) congress in Dublin, the European Biopharmaceutical Enterprises (EBE), together with the European Federation of Pharmaceutical Industries and Associations (EFPIA), describe the importance of customization.
Barbara Freischem, the director of the EBE, describes tailor-made therapy as a fundamental change to the traditional one-size-fits-all approach. She continues "With an increased understanding of the molecular mechanisms of diseases, we are now better able to adjust treatments so that patients get the right therapy at the right time. This also means that we can identify patients who do not benefit from certain medication and can avoid possible high risks of side effects. However, despite these important benefits, tailor-made therapy is not yet fully available to patients and policy makers still have to be convinced of the positive contribution to the sustainability and effeciency of European health care. "
The link to the press release